表紙
市場調査レポート

造血幹細胞移植:パイプライン製品の分析

Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 251517
出版日 ページ情報 英文 94 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
造血幹細胞移植:パイプライン製品の分析 Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2016
出版日: 2016年04月27日 ページ情報: 英文 94 Pages
概要

造血幹細胞移植 (HSCT) とは、骨髄や免疫系が損傷している患者の造血機能を再建するための、自家または同種異系の幹細胞の静脈内 (IV) 移植のことを指します。予見されているリスク要因には、出血や感染症、血栓症、心血管疾患などが含まれます。主な治療法には免疫抑制剤などがあります。

当レポートでは、世界各国での造血幹細胞移植向け治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

造血幹細胞移植の概要

治療薬の開発

  • パイプライン製品の概要

造血幹細胞移植:企業で開発中の治療薬

造血幹細胞移植:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

造血幹細胞移植:企業で開発中の製品

造血幹細胞移植の治療薬開発に従事している企業

  • Actinium Pharmaceuticals, Inc.
  • Athersys, Inc.
  • BioLineRx, Ltd.
  • Cell2B S.A.
  • Celldex Therapeutics, Inc.
  • FibroGen, Inc.
  • Novartis AG
  • P2D Bioscience
  • Polyphor Ltd.
  • TaiGen Biotechnology Co., Ltd.
  • Targazyme, Inc.
  • TikoMed AB

造血幹細胞移植:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

造血幹細胞移植:最近のパイプライン動向

造血幹細胞移植:休止中のプロジェクト

造血幹細胞移植:開発が中止された製品

造血幹細胞移植:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7880IDB

Summary

Global Markets Direct's, 'Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2016', provides an overview of the Hematopoietic Stem Cell Transplantation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hematopoietic Stem Cell Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hematopoietic Stem Cell Transplantation and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hematopoietic Stem Cell Transplantation
  • The report reviews pipeline therapeutics for Hematopoietic Stem Cell Transplantation by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hematopoietic Stem Cell Transplantation therapeutics and enlists all their major and minor projects
  • The report assesses Hematopoietic Stem Cell Transplantation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hematopoietic Stem Cell Transplantation

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hematopoietic Stem Cell Transplantation
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hematopoietic Stem Cell Transplantation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hematopoietic Stem Cell Transplantation Overview
  • Therapeutics Development
    • Pipeline Products for Hematopoietic Stem Cell Transplantation - Overview
  • Hematopoietic Stem Cell Transplantation - Therapeutics under Development by Companies
  • Hematopoietic Stem Cell Transplantation - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Hematopoietic Stem Cell Transplantation - Products under Development by Companies
  • Hematopoietic Stem Cell Transplantation - Companies Involved in Therapeutics Development
    • Actinium Pharmaceuticals, Inc.
    • Athersys, Inc.
    • BioLineRx, Ltd.
    • Cell2B S.A.
    • Celldex Therapeutics, Inc.
    • FibroGen, Inc.
    • Novartis AG
    • P2D Bioscience
    • Polyphor Ltd.
    • TaiGen Biotechnology Co., Ltd.
    • Targazyme, Inc.
    • TikoMed AB
  • Hematopoietic Stem Cell Transplantation - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Actimab-B - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • balixafortide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BL-8040 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • burixafor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Casin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CDX-301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CordSafe - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FG-6874 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HSC-835 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IBsolvMIR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Iomab-B - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PF-05285401 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • POL-5551 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TZ-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hematopoietic Stem Cell Transplantation - Recent Pipeline Updates
  • Hematopoietic Stem Cell Transplantation - Dormant Projects
  • Hematopoietic Stem Cell Transplantation - Discontinued Products
  • Hematopoietic Stem Cell Transplantation - Product Development Milestones
    • Featured News & Press Releases
      • Apr 06, 2016: Actinium Announces Webinar to Discuss SIERRA Trial -- Upcoming Pivotal, Phase 3 Clinical Study for Iomab-B
      • Mar 30, 2016: Actinium Receives Orphan Drug Designation From FDA for Iomab-B in Treating Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients
      • Mar 23, 2016: BioLineRx Announces Initiation of Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment
      • Mar 08, 2016: Actinium Pharmaceuticals Announces Filing of Provisional Patent Application Related to Commercial Scale Labeling and Processes for Iomab-B
      • Feb 20, 2016: Celldex Presents Preliminary Cohort Data from Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Harvest at the 2016 BMT Tandem Meeting
      • Feb 02, 2016: Actinium Pharmaceuticals Announces Participation at Upcoming Annual Meeting of Pre-Eminent Blood and Marrow Transplant Organization
      • Nov 30, 2015: Actinium to Present on Iomab-B at 8th Annual LD Micro Main Event Conference on December 2, 2015
      • Apr 23, 2015: Targazyme Announces FDA Concurrence On Targazyme's Special Protocol Assessment For A Planned Phase 3 Registration Trial For The Treatment Of Patients With Hematologic Malignancie
      • Mar 18, 2015: TaiGen Biotechnology Announces Burixafor Collaboration with Cellex and the University Hospital Carl Gustav Carus Dresden in Germany
      • Mar 17, 2015: Targazyme and M.D. Anderson Cancer Center Receive FDA IND Clearance for Phase I/II Study of TZ101-Treated Regulatory T Cells to Prevent Graft vs Host Disease in Patients Eligible for Hematologic Stem Cell Transplantation
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hematopoietic Stem Cell Transplantation, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by Athersys, Inc., H1 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by BioLineRx, Ltd., H1 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by Cell2B S.A. , H1 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by Celldex Therapeutics, Inc., H1 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by FibroGen, Inc., H1 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by Novartis AG, H1 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by P2D Bioscience, H1 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by Polyphor Ltd., H1 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by Targazyme, Inc., H1 2016
  • Hematopoietic Stem Cell Transplantation - Pipeline by TikoMed AB, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Hematopoietic Stem Cell Transplantation Therapeutics - Recent Pipeline Updates, H1 2016
  • Hematopoietic Stem Cell Transplantation - Dormant Projects, H1 2016
  • Hematopoietic Stem Cell Transplantation - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Hematopoietic Stem Cell Transplantation, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top